SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.

As Alvotech reported its first annual financial results, the company spoke of the imminent FDA inspection at its Icelandic manufacturing facility. An earlier inspection has so far put the kibosh on US approval for Alvotech’s proposed Humira (adalimumab) biosimilar.

After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI drug discovery is more predictable, efficient and cost-effective than the conventional bench-to-bed model. AI's limitations and validations, why the industry should get excited about algorithms, data sets and deep learning are other topics to consider in this fast-growing field. 

After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI drug discovery is more predictable, efficient and cost-effective than the conventional bench-to-bed model. AI's limitations and validations, why the industry should get excited about algorithms, data sets and deep learning are other topics to consider in this fast-growing field.